Toxicity of antirheumatic and anti-inflammatory drugs in children

Clinical Rheumatology

Volumn 17, Issue 6, 1998, Pages 505-510

  Flato B ^a   Vinje, O ^a   Forre O ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Children; DMARD; NSAID; Toxicity

Indexed keywords

ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; GOLD; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM;

ABDOMINAL PAIN; ADOLESCENT; ALOPECIA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHILD; DIARRHEA; EDEMA; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; PRURITUS; RASH; RHEUMATIC DISEASE;

EID: 0031672591     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf01451288     Document Type: Article

References (36)

1. Fries JF. Toward an understanding of patient outcome measurement. Arthritis Rheum 1983;26:697-704.
2. Gare BA, Fasth A. The natural history of juvenile chronic arthritis: a population based cohort study. II. Outcome. J Rheumatol 1995;22:308-19.
3. Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994;37:1761-9.
4. Graham LD, Myones BL, Rivas-Chacon RF, Pachman LM. Morbidity associated with long-term methotrexate therapy in juvenile rheumatoid arthritis. J Pediatr 1992;120:468-73.
5. Dowd JE, Cimaz R, Fink CW. Nonsteroidal antiinflammatory drug-induced gastroduodenal injury in children. Arthritis Rheum 1995;38:1225-31.
6. Keenan GF, Giannini EH, Athreya BH. Clinically significant gastropathy associated with nonsteroidal antiinflammatory drug use in children with juvenile rheumatoid arthritis. J Rheumatol 1995;22:1149-51.
7. Giannini EH, Cassidy JT, Brewer EJ, Shaikov A, Maximov A, Kuzmina N. Comparative efficacy and safety of advanced drug therapy in children with juvenile rheumatoid arthritis. Semin Arthritis Rheum 1993;23:34-46.
8. Williams PL, Ansell BM, Bell A, Cain AR, Chamberlain MA, Clarke AK, et al. Multicentre study of piroxicam versus naproxen in juvenile chronic arthritis, with special reference to problem areas in clinical trials of nonsteroidal anti-inflammatory drugs in childhood. Br J Rheumatol 1986;25:67-71.
9. Kvien TK, Høyeraal HM, Sandstad B. Slow acting antirheumatic drugs in patients with juvenile rheumatoid arthritis - evaluated in a randomized, parallel 50-week clinical tria. J Rheumatol 1985;12:533-9.
10. Fries JF, Williams CA, Bloch DA. The relative toxicity of nonsteroidal antiinflammatory drugs. Arthritis Rheum 1991; 34:1353-60.
11. Fries JF, Williams CA, Ramey D, Bloch DA. The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum 1993,36:297-306.
12. Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/ toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthritis Rheum 1992;35:1117-25.
13. Brewer EJ, Baas J, Baum J, Cassidy JT, Fink C, Jacobs J, et al. Current proposed revision of JRA Criteria. JRA Criteria Subcommittee of the Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Section of The Arthritis Foundation. Arthritis Rheum 1977;20(suppl):195-9.
14. Goie The HS, Steven MM, van der Linden SM, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a comparison of the Rome, New York and modified New York criteria in patients with a positive clinical history screening test for ankylosing spondylitis. Br J Rheumatol 1985;24:242-9.
15. Lambert JR, Ansell BM, Stephenson E, Wright V. Psoriatic arthritis in childhood. Clin Rheum Dis 1976;2:339-52.
16. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts) [Review]. N Engl J Med 1975;292:344-7.
17. Flatø B, Aasland A, Vandvik IH, Førre Ø. Outcome and predictive factors in children with chronic idiopathic musculoskeletal pain. Clin Exp Rheumatol 1997;15:561-8.
18. Vandvik IH, Høyeraal HM, Fagertun H. Chronic family difficulties and stressful life events in recent onset juvenile arthritis. J Rheumatol 1989;16:1088-92.
19. Flatø B, Aasland A, Vinje O, Førre Ø. Outcome and predictive factors in juvenile rheumatoid arthritis and juvenile spondylar-thropathy. J Rheumatol 1998;25:366-75.
20. Fries JF, Spitz PW, Williams CA, Bloch DA, Singh G, Hubert HB. A toxicity index for comparison of side effects among different drugs. Arthritis Rheum 1990;33:121-30.
21. Barron KS, Person DA, Brewer EJ. The toxicity of nonsteroidal antiinflammatory drugs in juvenile rheumatoid arthritis. J Rheumatol 1982;9:149-55.
22. Hermaszewski R, Hayllar J, Woo P. Gastro-duodenal damage due to non-steroidal anti-inflammatory drugs in children. Br J Rheumatol 1993;32:69-72.
23. Mulberg AE, Linz C, Bern E, Tucker L, Verhave M, Grand RJ. Identification of nonsteroidal antiinflammatory drug-induced gastroduodenal injury in children with juvenile rheumatoid arthritis. J Pediatr 1993;122:647-9.
24. Giannini EH, Brewer EJ, Miller ML, Gibbas D, Passo MH, Hoyeraal HM, et al. Ibuprofen suspension in the treatment of juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. J Pediatr 1990;117:645-52.
25. Kvien TK, Høyeraal HM, Sandstad B. Naproxen and acetylsalicylic acid in the treatment of pauciarticular and polyarticular juvenile rheumatoid arthritis. Assessment of tolerance and efficacy in a single-centre 24-week double-blind parallel study. Scand J Rheumatol 1984;13:342-50.
26. Grondin C, Malleson P, Petty RE. Slow-acting antirheumatic drugs in chronic arthritis of childhood [Review]. Semin Arthritis Rheum 1988;18:38-47.
27. Garcia-Morteo O, Maldonado-Cocco JA, Cuttica R, Garay SM. Piroxicam in juvenile rheumatoid arthritis. Eur J Rheumatol Inflamm 1987;8:49-53.
28. Cassidy JT, Petty RE. Juvenile rheumatoid arthritis. In: Cassidy JT, Petty RE, editors. Textbook of pediatric rheumatology, 3rd edn. Philadelphia: Saunders, 1995;5:187-98.
29. Duffy CM, Arsenault L, Duffy KNW. Level of agreement between parents and children in rating dysfunction in juvenile rheumatoid arthritis and juvenile spondyloarthritides. J Rheumatol 1993;20:2134-9.
30. Doherty E, Yanni G, Conroy RM, Bresnihan B. A comparison of child and parent ratings of disability and pain in juvenile chronic arthritis. J Rheumatol 1993;20:1563-6.
31. Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994;37:1761-9.
32. Benestad B, Vinje O, Veierød MB, Vandvik IH. Quantitative and qualitative assessments of pain in children with juvenile chronic arthritis based on the Norwegian version of the Paediatric Pain Questionnaire. Scand J Rheumatol 1996;25:293-9.
33. Hollingworth P. The use of non-steroidal anti-inflammatory drugs in paediatric rheumatic diseases [Review]. Br J Rheumatol 1993;32:73-7.
34. Wallace CA, Sherry DD. Preliminary report of higher dose methotrexate treatment in juvenile rheumatoid arthritis. J Rheumatol 1992;19:1604-7.
35. Makela AL, Olkkola KT, Mattila MJ. Steady state pharmacokinetics of piroxicam in children with rheumatic diseases. Eur J Clin Pharmacol 1991;41:79-81.
36. Albertioni F, Flatø B, Seideman P, Beck O, Vinje O, Peterson C, Eksborg S. Methotrexate in juvenile rheumatoid arthritis. Evidence of age dependent pharmacokinetics. Eur J Clin Pharmacol 1995;47:507-11.